S68F (p.Ser68Phe) variant of AGT (Angiotensinogen)

S68F (p.Ser68Phe) in AGT (Angiotensinogen) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.44 / 1. The record also includes population frequency data and structural context.

S68F (p.Ser68Phe) variant details